A Study to Evaluate the Safety and Tolerability of Subcutaneous Treprostinil and Pharmacokinetics of a Novel LY900014 Formulation in Healthy Japanese Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Jun 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Insulin lispro (Primary) ; Treprostinil (Primary)
Indications Pulmonary arterial hypertension; Type 1 diabetes mellitus; Type 2 diabetes mellitus
Focus Adverse reactions; Pharmacokinetics
Sponsors Eli Lilly and Company

15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
29 Jul 2016 Status changed from active, no longer recruiting to completed.
15 Jul 2016 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com